AR088579A1 - Formulaciones de anticuerpos - Google Patents
Formulaciones de anticuerposInfo
- Publication number
- AR088579A1 AR088579A1 ARP120104056A AR088579A1 AR 088579 A1 AR088579 A1 AR 088579A1 AR P120104056 A ARP120104056 A AR P120104056A AR 088579 A1 AR088579 A1 AR 088579A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- cdr
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Materials For Medical Uses (AREA)
Abstract
Se proporcionan formulaciones que comprenden un anticuerpo anti-IL-1 3, incluyendo formulaciones farmacéuticas y métodos de uso de dichas formulaciones. Reivindicación 1: Una formulación que comprende un anticuerpo anti-IL13, en donde la concentración de anticuerpo en la formulación es de al menos 100 mg/mL y la viscosidad de la formulación es inferior a 15 centipoise (cP) a 25ºC. Reivindicación 2: La formulación de acuerdo con la reivindicación 1, en donde el anticuerpo anti-IL13 comprende tres CDR de cadena pesada, donde CDR-H1 tiene la secuencia de aminoácidos de SEQ ID Nº 1, CDR-H2 tiene la secuencia de aminoácidos de SEQ ID Nº 2 y CDR-H3 tiene la secuencia de aminoácidos de SEQ ID Nº 3 y tres CDR de cadena liviana, donde CDR-L1 tiene la secuencia de aminoácidos de SEQ ID Nº 4, CDR-L2 tiene la secuencia de aminoácidos de SEQ ID Nº 5 y CDR-L3 tiene la secuencia de aminoácidos de SEQ ID Nº 6. Reivindicación 11: La formulación de acuerdo con la reivindicación 1 que comprende tampón de acetato de histidina, pH 5,4 a 6,0, en donde la concentración de acetato de histidina en el tampón es de entre 5 mM y 40 mM. Reivindicación 12: La formulación de acuerdo con la reivindicación 11, que también comprende un poliol y un tensioactivo, en donde la concentración del poliol en la formulación es de entre 100 mM y 200 mM y la concentración del tensioactivo en la formulación es de entre el 0,01% y el 0,1%. Reivindicación 13: La formulación de acuerdo con la reivindicación 12, en donde el poliol es sacarosa y el tensioactivo es polisorbato 20.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553916P | 2011-10-31 | 2011-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088579A1 true AR088579A1 (es) | 2014-06-18 |
Family
ID=48192677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104056 AR088579A1 (es) | 2011-10-31 | 2012-10-30 | Formulaciones de anticuerpos |
| ARP210103246A AR124140A2 (es) | 2011-10-31 | 2021-11-24 | Formulaciones de anticuerpos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103246A AR124140A2 (es) | 2011-10-31 | 2021-11-24 | Formulaciones de anticuerpos |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10000562B2 (es) |
| EP (3) | EP4218937A3 (es) |
| JP (4) | JP6120452B2 (es) |
| KR (4) | KR20140084078A (es) |
| CN (4) | CN108704132A (es) |
| AR (2) | AR088579A1 (es) |
| AU (3) | AU2012332767C1 (es) |
| BR (1) | BR112014008864B1 (es) |
| CA (2) | CA3078979C (es) |
| DK (1) | DK3091029T5 (es) |
| ES (1) | ES2936387T3 (es) |
| FI (1) | FI3091029T3 (es) |
| HK (1) | HK1201857A1 (es) |
| HR (1) | HRP20230153T1 (es) |
| HU (1) | HUE061728T2 (es) |
| IL (2) | IL232053B (es) |
| LT (1) | LT3091029T (es) |
| MX (2) | MX363226B (es) |
| MY (2) | MY197851A (es) |
| PL (1) | PL3091029T3 (es) |
| PT (1) | PT3091029T (es) |
| RS (1) | RS63948B1 (es) |
| RU (1) | RU2665810C2 (es) |
| SG (1) | SG11201401903PA (es) |
| SI (1) | SI3091029T1 (es) |
| WO (1) | WO2013066866A1 (es) |
| ZA (2) | ZA201401779B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19177059T1 (de) | 2010-10-01 | 2021-10-07 | Modernatx, Inc. | N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| WO2013066426A2 (en) | 2011-06-24 | 2013-05-10 | Kci Licensing, Inc. | Reduced-pressure dressings employing tissue-fixation elements |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HUE057725T2 (hu) | 2011-10-03 | 2022-06-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása |
| LT2771031T (lt) | 2011-10-28 | 2018-08-27 | Prothena Biosciences Limited | Humanizuoti antikūnai, kurie atpažįsta alfa sinukleiną |
| MX363226B (es) | 2011-10-31 | 2019-03-15 | Genentech Inc | Formulaciones de anticuerpos. |
| HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
| MX360778B (es) | 2012-01-27 | 2018-11-16 | Prothena Biosciences Ltd | Anticuerpos humanizados que reconocen alfa-sinucleína. |
| JP2015516143A (ja) | 2012-04-02 | 2015-06-08 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| SMT202200337T1 (it) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| MY193481A (en) | 2013-09-13 | 2022-10-17 | Genentech Inc | Method and compositions comprising purified recombinant polypeptides |
| PL3044323T3 (pl) | 2013-09-13 | 2022-06-27 | F.Hoffmann-La Roche Ag | Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| WO2015079977A1 (ja) * | 2013-11-26 | 2015-06-04 | シャープ株式会社 | 抗体分離方法、抗体評価方法、医薬の評価方法、及び、抗体の２次元電気泳動用キット |
| US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| WO2016102068A1 (en) | 2014-12-23 | 2016-06-30 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin prefilled container |
| EP4276108A3 (en) | 2016-04-27 | 2024-01-24 | AbbVie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| WO2018039591A1 (en) * | 2016-08-25 | 2018-03-01 | California Institute Of Technology | Ascaroside treatment of autoimmune and inflammatory diseases |
| HRP20231015T1 (hr) * | 2016-09-23 | 2023-12-08 | F. Hoffmann-La Roche Ag | Upotreba antagonista il-13 u liječenju atopičnog dermatitisa |
| CN120392659A (zh) * | 2017-01-11 | 2025-08-01 | 赛特瑞恩股份有限公司 | 稳定的液体调配物 |
| JP2019048091A (ja) * | 2018-10-23 | 2019-03-28 | ニプロ株式会社 | デクスメデトミジン注射液を充填したプレフィルドシリンジ |
| KR102578103B1 (ko) * | 2019-01-02 | 2023-09-18 | 도소 가부시키가이샤 | 광 산란 검출기 및 광 산란 검출기를 위한 방법 |
| PH12021551916A1 (en) | 2019-02-18 | 2022-05-23 | Lilly Co Eli | Therapeutic antibody formulation. |
| KR20220122993A (ko) * | 2019-11-26 | 2022-09-05 | 코메라 라이프 사이언시스, 인코포레이티드 | 바이오폴리머 제형을 위한 부형제 화합물 |
| AU2021365008A1 (en) * | 2020-10-22 | 2023-06-08 | Allakos Inc. | Anti-siglec-8 antibody formulations |
| TWI847170B (zh) | 2021-07-16 | 2024-07-01 | 美商德米拉股份有限公司 | 用於治療異位性皮炎之il-13抗體 |
| TWI859566B (zh) | 2021-08-13 | 2024-10-21 | 美商德米拉股份有限公司 | 用於治療異位性皮膚炎之il-13抗體 |
| US20240425578A1 (en) | 2021-09-15 | 2024-12-26 | Dermira, Inc. | Il-13 inhibitors for the treatment of prurigo nodularis |
| WO2023215769A1 (en) | 2022-05-05 | 2023-11-09 | Dermira, Inc. | Il-13 antibodies for the treatment of atopic dermatitis |
| EP4540284A2 (en) | 2022-06-17 | 2025-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind interleukin 13 and methods of use |
| AU2024233079A1 (en) | 2023-03-08 | 2025-09-04 | Dermira, Inc. | Il-13 antibodies for the treatment of atopic dermatitis |
| WO2025076280A1 (en) | 2023-10-05 | 2025-04-10 | Ashibio, Inc. | Methods and compositions for treating mmp-9 mediated disorders |
| WO2025128990A1 (en) | 2023-12-14 | 2025-06-19 | Dermira, Inc. | Il-13 antibodies for the treatment of perennial allergic rhinitis |
| WO2025128984A1 (en) | 2023-12-14 | 2025-06-19 | Dermira, Inc. | Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps |
| WO2025137410A1 (en) * | 2023-12-20 | 2025-06-26 | Apogee Therapeutics, Inc. | Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine |
| WO2025137523A2 (en) * | 2023-12-20 | 2025-06-26 | Apogee Therapeutics, Inc. | Pharmaceutical formulations of antibodies that bind interleukin 13 |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
| WO2025155802A1 (en) * | 2024-01-19 | 2025-07-24 | Allakos Inc. | Anti-siglec-6 antibody formulations |
| WO2025184453A1 (en) | 2024-03-01 | 2025-09-04 | Dermira, Inc. | Il-13 antibodies for the treatment of post-inflammatory hyperpigmentation or hypopigmentation of skin |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP2876058B2 (ja) | 1986-08-18 | 1999-03-31 | エミスフィア・テクノロジーズ・インコーポレイテッド | 薬物送達システム |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| EP1013270A3 (en) | 1992-12-02 | 2001-03-28 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
| EP0779806B2 (en) | 1994-09-09 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Sustained release preparation containing metal salt of a peptide |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| RU2161502C2 (ru) | 1995-06-07 | 2001-01-10 | Элкермес Контролд Терапьютикс, Инк. | Композиция для пролонгированного высвобождения гормона роста человека |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク． | 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| JP2003512821A (ja) | 1999-10-04 | 2003-04-08 | メディカゴ インコーポレイテッド | 外来性遺伝子の転写調節方法 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| WO2002030463A2 (en) | 2000-10-12 | 2002-04-18 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| MXPA04003901A (es) * | 2001-11-07 | 2004-07-08 | Cytos Biotechnology Ag | Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas. |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US8937045B2 (en) | 2003-02-28 | 2015-01-20 | Ares Trading S.A. | Liquid formulations of tumor necrosis factor-binding proteins |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| CA2519408C (en) | 2003-04-04 | 2011-01-18 | Genentech, Inc. | High concentration antibody and protein formulations |
| AR045614A1 (es) * | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
| ES2385038T3 (es) | 2003-12-23 | 2012-07-17 | Genentech, Inc. | Nuevos anticuerpos Anti-IL 13 y usos de los mismos |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2007036745A2 (en) | 2005-09-30 | 2007-04-05 | Medimmune Limited | Interleukin-13 antibody composition |
| EP2532678A1 (en) * | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| JP5405122B2 (ja) * | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| TWI395754B (zh) * | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| CL2008000058A1 (es) * | 2007-01-09 | 2008-05-23 | Wyeth Corp | Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden. |
| CA2676881C (en) * | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| PL2367542T3 (pl) * | 2008-12-03 | 2014-05-30 | Astellas Deutschland Gmbh | Doustne formy dawkowania bendamustyny |
| EP2403874A1 (en) * | 2009-03-06 | 2012-01-11 | Genentech, Inc. | Antibody formulation |
| CN107496917B (zh) | 2010-02-26 | 2021-06-11 | 诺沃—诺迪斯克有限公司 | 包含稳定抗体的组合物 |
| RU2584232C2 (ru) * | 2010-03-22 | 2016-05-20 | Дженентек, Инк. | Композиции и способы, используемые для стабилизации белоксодержащих готовых форм |
| BR112012027828A2 (pt) | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
| CN103501825B (zh) | 2011-05-02 | 2017-03-15 | 免疫医疗公司 | 用于小体积施用的同种异型选择的抗体的超滤浓缩 |
| MX363226B (es) * | 2011-10-31 | 2019-03-15 | Genentech Inc | Formulaciones de anticuerpos. |
-
2012
- 2012-10-30 MX MX2014004992A patent/MX363226B/es unknown
- 2012-10-30 EP EP22208284.4A patent/EP4218937A3/en active Pending
- 2012-10-30 SI SI201232018T patent/SI3091029T1/sl unknown
- 2012-10-30 CA CA3078979A patent/CA3078979C/en active Active
- 2012-10-30 JP JP2014539136A patent/JP6120452B2/ja active Active
- 2012-10-30 HR HRP20230153TT patent/HRP20230153T1/hr unknown
- 2012-10-30 KR KR20147011246A patent/KR20140084078A/ko not_active Ceased
- 2012-10-30 WO PCT/US2012/062572 patent/WO2013066866A1/en not_active Ceased
- 2012-10-30 RS RS20230095A patent/RS63948B1/sr unknown
- 2012-10-30 DK DK16169916.0T patent/DK3091029T5/da active
- 2012-10-30 AU AU2012332767A patent/AU2012332767C1/en active Active
- 2012-10-30 LT LTEP16169916.0T patent/LT3091029T/lt unknown
- 2012-10-30 CN CN201810964732.0A patent/CN108704132A/zh active Pending
- 2012-10-30 HK HK15102358.5A patent/HK1201857A1/xx unknown
- 2012-10-30 PL PL16169916.0T patent/PL3091029T3/pl unknown
- 2012-10-30 CA CA2849210A patent/CA2849210C/en active Active
- 2012-10-30 HU HUE16169916A patent/HUE061728T2/hu unknown
- 2012-10-30 AR ARP120104056 patent/AR088579A1/es not_active Application Discontinuation
- 2012-10-30 SG SG11201401903PA patent/SG11201401903PA/en unknown
- 2012-10-30 EP EP12846324.7A patent/EP2773662A4/en not_active Withdrawn
- 2012-10-30 CN CN201280053245.XA patent/CN104039826A/zh active Pending
- 2012-10-30 MY MYPI2018001912A patent/MY197851A/en unknown
- 2012-10-30 CN CN202210876554.2A patent/CN116077644A/zh active Pending
- 2012-10-30 ES ES16169916T patent/ES2936387T3/es active Active
- 2012-10-30 MY MYPI2014001225A patent/MY187874A/en unknown
- 2012-10-30 RU RU2014116070A patent/RU2665810C2/ru active
- 2012-10-30 EP EP16169916.0A patent/EP3091029B1/en active Active
- 2012-10-30 CN CN201810964731.6A patent/CN109078182B/zh active Active
- 2012-10-30 KR KR1020177022308A patent/KR101994809B1/ko active Active
- 2012-10-30 KR KR1020207015572A patent/KR102259829B1/ko active Active
- 2012-10-30 PT PT161699160T patent/PT3091029T/pt unknown
- 2012-10-30 FI FIEP16169916.0T patent/FI3091029T3/fi active
- 2012-10-30 KR KR1020197018310A patent/KR20190077127A/ko not_active Ceased
- 2012-10-31 BR BR112014008864-0A patent/BR112014008864B1/pt active IP Right Grant
-
2014
- 2014-03-11 ZA ZA2014/01779A patent/ZA201401779B/en unknown
- 2014-04-10 IL IL232053A patent/IL232053B/en active IP Right Grant
- 2014-04-23 US US14/259,882 patent/US10000562B2/en active Active
- 2014-04-24 MX MX2019002979A patent/MX2019002979A/es unknown
-
2016
- 2016-06-08 JP JP2016114267A patent/JP6272950B2/ja active Active
- 2016-08-05 AU AU2016210757A patent/AU2016210757A1/en not_active Abandoned
-
2017
- 2017-10-18 JP JP2017202159A patent/JP2018048166A/ja not_active Withdrawn
-
2018
- 2018-06-07 US US16/002,932 patent/US10947307B2/en active Active
- 2018-09-19 AU AU2018232943A patent/AU2018232943B2/en active Active
-
2019
- 2019-03-11 ZA ZA2019/01490A patent/ZA201901490B/en unknown
- 2019-06-25 JP JP2019116979A patent/JP6921148B2/ja active Active
-
2020
- 2020-07-22 IL IL276234A patent/IL276234B/en unknown
-
2021
- 2021-02-04 US US17/167,754 patent/US12492247B2/en active Active
- 2021-11-24 AR ARP210103246A patent/AR124140A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088579A1 (es) | Formulaciones de anticuerpos | |
| AR110659A1 (es) | Proteínas de unión a antígenos anti-neuropilin y método para su uso | |
| ES2523740T3 (es) | Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 | |
| PE20240813A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodo para su uso | |
| ES2721753T3 (es) | Anticuerpos contra IL-6 y usos de los mismos | |
| PE20040519A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| AR092216A1 (es) | Formulaciones estables de anticuerpos contra tslp | |
| AR097651A1 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| CO6480962A2 (es) | Anticuerpos anti-vegf y sus usos | |
| FI4339615T3 (sv) | Anti-PD-1-antikroppar för användande vid behandling av cancer | |
| JP2016531914A5 (es) | ||
| PE20130580A1 (es) | Proteinas terapeuticas de union a dll4 | |
| PE20220279A1 (es) | Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos | |
| PE20240819A1 (es) | Anticuerpos anti-hla-g y uso de estos | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20121649A1 (es) | Anticuerpos monoclonales frente a progastrina y sus usos | |
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| PE20130214A1 (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
| NZ596712A (en) | Anti cxcr4 antibodies for the treatment of hiv | |
| PE20212324A1 (es) | Anticuerpos que reconocen tau | |
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| PE20121645A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |